Quantamental Technologies LLC Makes New $49,000 Investment in Intra-Cellular Therapies Inc (NASDAQ:ITCI)

Quantamental Technologies LLC purchased a new position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 3,805 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

A number of other large investors have also modified their holdings of ITCI. Dimensional Fund Advisors LP boosted its stake in Intra-Cellular Therapies by 1.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,444,223 shares of the biopharmaceutical company’s stock worth $16,450,000 after buying an additional 24,335 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Intra-Cellular Therapies by 883.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,361 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 9,307 shares during the last quarter. First Mercantile Trust Co. boosted its stake in Intra-Cellular Therapies by 12.3% in the 1st quarter. First Mercantile Trust Co. now owns 11,522 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 1,265 shares during the last quarter. LLBH Private Wealth Management LLC acquired a new stake in Intra-Cellular Therapies in the 1st quarter worth about $263,000. Finally, Wasatch Advisors Inc. lifted its stake in shares of Intra-Cellular Therapies by 19.0% in the 1st quarter. Wasatch Advisors Inc. now owns 2,361,619 shares of the biopharmaceutical company’s stock valued at $28,765,000 after purchasing an additional 377,561 shares in the last quarter. 68.97% of the stock is currently owned by hedge funds and other institutional investors.

ITCI has been the topic of several research analyst reports. BidaskClub raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 7th. Cantor Fitzgerald set a $27.00 price objective on Intra-Cellular Therapies and gave the company a “buy” rating in a research note on Tuesday. Leerink Swann reaffirmed a “buy” rating on shares of Intra-Cellular Therapies in a research note on Tuesday. ValuEngine lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Finally, Zacks Investment Research lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, July 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Intra-Cellular Therapies has an average rating of “Buy” and a consensus price target of $23.63.



Shares of NASDAQ ITCI traded down $0.52 during midday trading on Friday, hitting $9.94. The stock had a trading volume of 1,078,444 shares, compared to its average volume of 706,272. The company has a market capitalization of $548.39 million, a price-to-earnings ratio of -3.50 and a beta of 1.19. Intra-Cellular Therapies Inc has a 1-year low of $7.41 and a 1-year high of $23.62. The company has a quick ratio of 8.86, a current ratio of 8.86 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average price of $8.88 and a 200 day moving average price of $11.75.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.15. On average, research analysts forecast that Intra-Cellular Therapies Inc will post -3.39 EPS for the current year.

In related news, Director Christopher D. Alafi purchased 125,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 30th. The shares were purchased at an average cost of $8.52 per share, with a total value of $1,065,000.00. Following the transaction, the director now owns 341,223 shares of the company’s stock, valued at approximately $2,907,219.96. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher D. Alafi purchased 485,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $10.26 per share, for a total transaction of $4,976,100.00. Following the completion of the transaction, the director now directly owns 341,223 shares in the company, valued at approximately $3,500,947.98. The disclosure for this purchase can be found here. Insiders own 18.20% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

See Also: Are FAANG stocks a good investment?

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.